Impact of breast cancer genetic testing in Brazilian patients: insights from the MAGENTA study

dc.contributor.authorEvelin Scarelli
dc.contributor.authorCarolina Meyn Teixeira
dc.contributor.authorNathália Viana e Silva
dc.contributor.authorAndréa Silveira dos Santos Bredariol
dc.contributor.authorGiovana Sivieri Baracho
dc.contributor.authorFabiano Hahn Souza
dc.contributor.authorL. Holtz
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T19:59:55Z
dc.date.available2026-03-22T19:59:55Z
dc.date.issued2026
dc.description.abstractThe survey respondents in Brazil comprised a highly educated and financially secure group of patients. Although not generalizable to the entire Brazilian population, our results revealed that even in a highly educated and well-informed cohort there is a strong association between age and income level with genetic testing. These findings expose the real-world challenges for increasing genetic testing coverage in Brazil, where testing is only warranted in the private health system, highlighting the need for health policies to increase test availability for lower income brackets.
dc.identifier.doi10.3389/fonc.2025.1597891
dc.identifier.urihttps://doi.org/10.3389/fonc.2025.1597891
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/79382
dc.language.isoen
dc.publisherFrontiers Media
dc.relation.ispartofFrontiers in Oncology
dc.sourceAstraZeneca (Brazil)
dc.subjectGenetic testing
dc.subjectMedicine
dc.subjectCohort
dc.subjectBreast cancer
dc.subjectTest (biology)
dc.subjectOncology
dc.subjectHereditary Cancer
dc.subjectInternal medicine
dc.subjectPublic health
dc.subjectCohort study
dc.titleImpact of breast cancer genetic testing in Brazilian patients: insights from the MAGENTA study
dc.typearticle

Files